The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TTOO | -99.17% | -100% | -92.89% | -100% |
| S&P | +16.23% | +94.45% | +14.22% | +253% |
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
A revenue drop and a reverse stock split worried investors.
The diagnostic test maker's panels could help to combat the spread of new coronavirus variants.
| Q3 2024 | YOY Change | |
|---|---|---|
| Revenue | $1.99M | 0.0% |
| Gross Profit | -$2.12M | 0.0% |
| Gross Margin | -106.60% | 0.0% |
| Market Cap | $34.44M | 0.0% |
| Market Cap / Employee | $0.30M | 0.0% |
| Employees | 113 | 0.0% |
| Net Income | -$10.12M | 0.0% |
| EBITDA | -$10.10M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2024 | YOY Change | |
|---|---|---|
| Net Cash | $2.08M | 0.0% |
| Accounts Receivable | $2.03M | 0.0% |
| Inventory | 3.8 | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.30M | 0.0% |
| Short Term Debt | $13.65M | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Return On Assets | -140.00% | 0.0% |
| Return On Invested Capital | -21.42% | 0.0% |
| Q3 2024 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6.25M | 0.0% |
| Operating Free Cash Flow | -$6.25M | 0.0% |
| Metric | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.28 | -0.43 | -0.78 | -5.81 | - |
| Price to Sales | 3.54 | 2.13 | 10.51 | 4.59 | - |
| Price to Tangible Book Value | -1.28 | -0.43 | -0.78 | -5.81 | - |
| Enterprise Value to EBITDA | -6.41 | -4.67 | -9.49 | -5.16 | - |
| Total Debt | $49.50M | $49.50M | $19.22M | $18.94M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
